<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019565</url>
  </required_header>
  <id_info>
    <org_study_id>980163</org_study_id>
    <secondary_id>98-C-0163</secondary_id>
    <secondary_id>CDR0000066720</secondary_id>
    <nct_id>NCT00019565</nct_id>
    <nct_alias>NCT00001709</nct_alias>
  </id_info>
  <brief_title>PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy</brief_title>
  <official_title>The Use of Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) to Assess the Effects of Anti-neoplastic Therapy on Tumor Associated Vasculature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as PET and MRI scans, may help to measure a patient's&#xD;
      response to treatment.&#xD;
&#xD;
      PURPOSE: This diagnostic trial is studying how well PET and/or MRI scans work in assessing&#xD;
      changes in tumor blood supply in patients receiving antiangiogenesis therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the ability of positron emission tomography (PET) to assess the effect of&#xD;
           therapy directed against tumor vasculatures on tumor blood flow and tumor blood volume&#xD;
           in patients enrolled on a treatment protocol evaluating a therapeutic modality effecting&#xD;
           the tumor associated vasculature.&#xD;
&#xD;
        -  Evaluate the ability of PET to assess the effects of this type of therapy regimen on&#xD;
           tumor uptake of fluorodeoxyglucose in these patients.&#xD;
&#xD;
        -  Evaluate the ability of magnetic resonance imaging (MRI) to assess the effects of&#xD;
           therapy directed against the tumor vasculature on tumor blood flow and tumor vascular&#xD;
           density in these patients.&#xD;
&#xD;
        -  Compare the findings on PET and/or MRI with those obtained from conventional CT in this&#xD;
           patient population.&#xD;
&#xD;
      OUTLINE: This is a diagnostic study conducted concurrently with a therapeutic modality study.&#xD;
&#xD;
      Patients have magnetic resonance imaging and/or positron emission tomography (PET) scans&#xD;
      performed prior to start of therapy, 6 weeks and 16 weeks following the initiation of&#xD;
      therapy, and 6 weeks following the completion of therapy. Each scan requires about 1-3 hours.&#xD;
      Patients receive up to 3 different PET scans including tumor blood flow scan with H2015,&#xD;
      tumor blood volume scan with 11CO, and glucose uptake scan with fludeoxyglucose F 18.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 145 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">53</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Eligible for a treatment protocol evaluating a therapeutic modality that may have an&#xD;
             effect on tumor associated vasculature&#xD;
&#xD;
          -  Measurable or evaluable disease by standard CT or MRI&#xD;
&#xD;
          -  At least 1 lesion measuring greater than 2 cm in diameter&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No pacemakers, aneurysm clips, shrapnel injury, or implantable electronic devices&#xD;
&#xD;
          -  Weight no greater than 136 kilograms&#xD;
&#xD;
          -  No sensitivity to contrast agents that cannot be controlled with premedication&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven K. Libutti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

